ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,180.74
1.03%
US Tech 100
17,598.80
1.03%
Dow Jones
38,852.27
0.46%
Brent Oil
83.355
-0.14%
Bitcoin
63,313.07
0.23%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. LENZ Therapeutics Inc (LENZ) Quote

LENZ Therapeutics Inc

LENZ Therapeutics Inc (LENZ)

Sancus Lending Group Limited
16.18
-0.28
(-1.70%)
Closed May 07 4:00PM
Delayed by 15 minutes
16.47
0.29
(1.79%)
After Hours: 7:48PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
16.47
Bid
15.00
Ask
18.99
Volume
287,359
15.97 Day's Range 16.745
15.05 52 Week Range 24.59
Market Cap
934.896M
Previous Close
16.46
Open
16.74
Last Trade
1
@
16.74
Last Trade Time
Financial Volume
$ 4,729,142
VWAP
16.4573
Average Volume (3m)
138,606
Shares Outstanding
57,996,000
Dividend Yield
-
PE Ratio
-7.50
Earnings Per Share (EPS)
-2.15
Revenue
-
Net Profit
-124.65M

About LENZ Therapeutics Inc

Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert ... Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.lenz-tx.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
LENZ Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker LENZ. The last closing price for LENZ Therapeutics was $16.46. Over the last year, LENZ Therapeutics shares have traded in a share price range of $ 15.05 to $ 24.59.

LENZ Therapeutics currently has 57,996,000 shares outstanding. The market capitalization of LENZ Therapeutics is $934.90 million. LENZ Therapeutics has a price to earnings ratio (PE ratio) of -7.50.

LENZ Latest News

More News

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first...

May 01 2024
GlobeNewswire Inc.

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

– LNZ100 selected as lead candidate – Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours – Rapid onset and long duration...

April 03 2024
Business Wire

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

 Conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. EST LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company...

April 02 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.593.7153652392915.8816.7915.4924160716.23044055CS
4-3.73-18.465346534720.222.0715.0513125716.94042193CS
120.493.0663329161515.9824.5915.0513860618.17555335CS
260.493.0663329161515.9824.5915.0513860618.17555335CS
520.493.0663329161515.9824.5915.0513860618.17555335CS
1560.493.0663329161515.9824.5915.0513860618.17555335CS
2600.493.0663329161515.9824.5915.0513860618.17555335CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUVOHoldco Nuvo Group DG Ltd
$ 5.2108
(155.43%)
43.44M
XBPXBP Europe Holdings Inc
$ 3.4999
(65.09%)
55.73M
PLTNPlutoniam Acquisition Corporation
$ 9.40
(56.41%)
1.43M
PRFTPerficient Inc
$ 73.27
(52.30%)
11.68M
NRXPNRX Pharmaceuticals Inc
$ 3.05
(45.24%)
9.31M
LYRALyra Therapeutics Inc
$ 0.519
(-87.12%)
108.65M
GLYCGlycoMimetics Inc
$ 0.3165
(-82.70%)
41M
EYPTEyePoint Pharmaceuticals Inc
$ 11.15
(-43.52%)
9.65M
LGHLWLion Group Holding Ltd
$ 0.0047
(-32.86%)
100.74k
MMATMeta Materials Inc
$ 2.44
(-27.16%)
580.58k
LYRALyra Therapeutics Inc
$ 0.519
(-87.12%)
108.65M
SQQQProShares UltraPro Short QQQ
$ 10.70
(-3.43%)
94.71M
NKLANikola Corporation
$ 0.6497
(-1.19%)
89.11M
MARAMarathon Digital Holdings Inc
$ 20.695
(18.12%)
87.05M
TSLATesla Inc
$ 184.76
(1.97%)
84.41M

Discussion

View Full Feed
Mjmurr13 Mjmurr13 3 minutes ago
Any thoughts on the insignificantly small insider sells?
SONX
gail gail 3 minutes ago
uh oh, guess what……

….

i just noticed, on youtube, as i have marked the “American idol” page, it shows the number of views for each act and sadly, emmy and then abi got the most and then jack is 3rd and the rest dont have as many views. that tells me that emmy may win e
goldslacker2023 goldslacker2023 7 minutes ago
And the ones "railroading" shareholders into selling? I would not mind if was the "mother load". Let me know when the confetti's going. I will even add you in my tshirt logo then. Along with rump shaker, and....
GNCP
janice shell janice shell 7 minutes ago
Ahhh, I see.
doubbleup doubbleup 9 minutes ago
I wonder if we are NIST 800-53 certified?
Or if we are FedRAMP certified?
SDCH
newmedman newmedman 12 minutes ago
No, at night they are in their enclosures. Because of our climate here most all of our kids are inside at night and have gotten used to the herding thing. Except for our bears and stuff, some of them love the snow and cold.

Our indoor habitats are where I come in and the
trippininLaCoste trippininLaCoste 13 minutes ago
No, no reason to. Do you think for one minute he intends to willingly split the proceeds with shareholders ? He might. He might not.

I am going to assume the latter.

Has your sister spoken Darcy Klug?
Stockman1010101 Stockman1010101 13 minutes ago
So what you think the fire was in the storage building in Chicago 2 years ago, that burnt down all of TD Ameritrade trading records for the last 30 years. It was probably evidence to convict KG and other Hedge Fund managers of the crimes they committed against AMC and other stocks retail investors d
AMC
janice shell janice shell 15 minutes ago
Big difference— saying vs doing — obvious

He said he did it. He also said he can't control himself. I doubt there's a woman alive who doesn't believe it. So do most men.
janice shell janice shell 18 minutes ago
He's your Berlusconi, except Silvio was a much more successful businessman. .

Yes. And although he was a creep, he wasn't nearly as crude as Trumpty.
janice shell janice shell 19 minutes ago
Because it’s not obvious that he has raped anyone—

His own first wife said he raped her, and also yanked out a handful of her hair. She wrote that in a declaration in their divorce case. To get the settlement she wanted, she withdrew it.

But it was obviously true.
Biotechotcguy Biotechotcguy 20 minutes ago
Huh??? LMMAAOOOO Dude you always come in here typing a whole lot of nothing and giving zero links …. Just a bunch of word salads lol I can’t fake you serious.
BLPG
dstock07734 dstock07734 21 minutes ago
Fabulous post! Agree with you totally about the following.


Since 2014, poly-ICLC has been referred to as a component in the DCVax-L formulation, and not as an adjuvant treatment. Poly-ICLC was only referred to as an adjuvant treatment in the original 2010 trial.

NWBO
BNYPD BNYPD 23 minutes ago
CE means nothing ? are you kidding me
TXTM
declaes declaes 27 minutes ago
Company just let me know it will be tomorrow 7May
GRST
DKLN DKLN 28 minutes ago
Look - the pusher was wrong again. I suggest this clueless person let intelligent people do the thinking from now on.
MCIC
janice shell janice shell 28 minutes ago
Is it me or does Bree look like Michael T. Flynn in drag?

NO. That is SO MEAN!!!
Kool Aid Man Kool Aid Man 29 minutes ago
No one shorts penny crap...doing so is ghastly expensive, highly risky and offers paltry returns even if they prevail. Ignorance is astounding
SPZI
djjazzyjeff djjazzyjeff 29 minutes ago
All of the above all the above all the above like a song you said it!!!!!!!!!!!!!!
CYDY
djjazzyjeff djjazzyjeff 31 minutes ago
Yo why are you so mad relax damn
CYDY
arizona1 arizona1 32 minutes ago
Does anyone know how old Cricket was when the Noem family adopted her? Kristi makes it sound like they had Cricket practically forever but then she also says another family had trouble with her before she was adopted? The whole story makes no sense and now she thinks Biden should have had Command
flipper44 flipper44 32 minutes ago
Correct. It comprises the best formulation. This careful study took over a decade to complete, safety was irrefutably proven, and the best formulation utilized poly-SCLC with DCVax-l.
NWBO

Your Recent History

NASDAQ
LENZ
LENZ Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved